Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

10rx vs NiceRx

An in-depth comparison of two leading GLP-1 Providers

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
10rx logo

10rx

8.1
★★★★4.1/5

Best for: semaglutide at $99.67/month, 47% under the register median

Visit 10rx
VS
NiceRx logo

NiceRx

7.8
★★★3.9/5

Best for: compounded semaglutide at $199/month

Visit NiceRx

Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, 10rx opens cheaper — $99.67/mo against $199, and 10rx finishes ahead, 8.1 to 7.8. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.

Pricing

10rx

Injectablecompounded injection
$99.67/mo
semaglutide

Compounded; GLP-1 options as low as under $100/mo

Injectablecompounded injection
$149.67/mo
tirzepatide

Compounded GLP-1 + GIP

NiceRx

Compounded SemaglutideCompounded
$199/mo
semaglutide

First month $99 with promo

Compounded TirzepatideCompounded
$299/mo
tirzepatide

First month $199 with promo

What’s included

10rx

Covered by the monthly price

Medication

In the price

Clinician visits

In the price

Shipping

In the price

Lab work

Not stated

Coaching

Not stated

NiceRx

Covered by the monthly price

Medication

In the price

Clinician visits

In the price

Shipping

In the price

Lab work

Not stated

Coaching

Not stated

Score breakdown

Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.

10rx

8.1/10

Overall

NiceRx

7.8/10

Value25%

9.6A
vs
B
4.6

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

5.5A
vs
B
8.5

Accessibility10%

5.0A
vs
B
9.4

Support10%

7.0A
vs
B
7.0

Features & Coverage

Feature10rxNiceRx
Starting Price$99.67/mo$199/mo
Features8 features5 features
States AvailableNot disclosed46
Compounded✓ Yes
Brand Name
FSA/HSA Accepted
FDA WarningsNoneNone

About 10rx

10rx sets flat monthly rates on compounded GLP-1: semaglutide at $99.67, tirzepatide at $149.67, with NAD+ and sermorelin sold separately for energy and recovery. A free health quiz online reaches a board-certified telehealth doctor, who reads your history before writing anything, and licensed pharmacy partners handle discreet delivery. The company states it reaches every one of the 50 states. What it does not state is its operating company, its pharmacies, or any terms page.

Read our full 10rx review →

About NiceRx

NiceRx LLC lists compounded semaglutide at $199/mo and compounded tirzepatide at $299/mo, with first-month promos. It is LegitScript approved and sells in 46 states, excluding AK, MS, NJ and KS. Rob Stransky founded the company in 2022. Every batch is tested for sterility and potency.

Read our full NiceRx review →

Pros & Cons

10rx

What we like

  • Semaglutide at $99.67 a month, 47% below the $189 median for the same drug and form across this register
  • Tirzepatide at $149.67 a month, 44% below the $267 median for the same drug and form across this register
  • Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
  • The monthly figure covers medication, consult, shipping
  • No FDA warning letter matched this operator when we searched our enforcement register

Watch-outs

  • No state list is on record here, so whether it serves your state cannot be confirmed from this page
  • No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

NiceRx

What we like

  • Semaglutide at $199 a month, within the normal band around this register's $189 median for the same drug and form
  • Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
  • The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
  • The monthly figure covers medication, consult, shipping
  • Coverage is published for 46 states
  • No FDA warning letter matched this operator when we searched our enforcement register

Watch-outs

  • No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

Our Verdict

Winner: 10rx

10rx takes it, 8.1 against 7.8, and it is especially strong on semaglutide at $99.67/month, 47% under the register median. NiceRx is no weak second and may fit you better on compounded semaglutide at $199/month.

Choose 10rx if…

You want semaglutide at $99.67/month, 47% under the register median and an opening price near $99.67 a month.

Choose NiceRx if…

You want compounded semaglutide at $199/month and an opening price near $199 a month.

Ready to start? Vetted GLP-1 providers

Vetted telehealth providers that prescribe GLP-1 online.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.9

Oak

Semaglutide at $119/month, 37% under the register median

8.8

Found

Tirzepatide at $169/month, 37% under the register median

8.3

Telos Rx

Starting below a standard dose, with microdose tiers

10rx vs NiceRx: FAQ

Glossary

The words sellers use, defined. Tap any term.

Continue exploring 10rx and NiceRx head-to-heads in the same category.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.